Vaccine stocks are rocketing on race for a cure.
Just two days ago, we highlighted Moderna (MRNA), as one of the top opportunities.
As we noted, Moderna just dosed the first patient in a Phase I study being conducted by the National Institutes of Health. “This study is the first step in the clinical development of an mRNA vaccine against SARS-CoV-2, and we expect it to provide important information about safety and immunogenicity,” Moderna’s CMO, Tal Zaks, said, as quoted by Barron’s.
As MRNA gains momentum, BioNTech (BNTX) is just beginning to, as well.
In fact, shares are rocketing on news that it and Pfizer have entered the race to develop a vaccine. The two are reportedly entering clinical trials next month. “We believe that by pairing Pfizer’s development, regulatory and commercial capabilities with BioNTech’s mRNA vaccine technology and expertise as one of the industry leaders, we are reinforcing our commitment to do everything we can to combat this escalating pandemic, as quickly as possible,” Mikael Dolsten, Pfizer’s chief scientific officer said, as quoted by Barron’s.
Both are still solid investing opportunities, as the world races for a coronavirus vaccine.
All as the U.S. government warns we could see the pandemic last up to 18 months or longer, and “include multiple waves of illness,” as noted by CNN. Hospitals are also sounding the alarms on short supplies with the outbreak showing no signs of slowing. And to date, 9,000 Americans have now tested positive, with 149 deaths. Be safe out there.